Experimental pulmonary aspergillosis due to Aspergillus terreus: Pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B

Journal of Infectious Diseases

Volumn 188, Issue 2, 2003, Pages 305-319

  Walsh, Thomas J ^a   Petraitis, Vidmantas ^a   Petraitiene, Ruta ^a   Field Ridley, Aida ^a   Sutton, Deanna ^c   Ghannoum, Mahmoud ^d   Sein, Tin ^a   Schaufele, Robert ^a   Peter, Joanne ^a   Bacher, John ^b   Casler, Heather ^a   Armstrong, Derek ^a   Espinel Ingroff, Anna ^e   Rinaldi, Michael G ^c   Lyman, Caron A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG EFFECT; FUNGICIDAL ACTIVITY; LUNG ASPERGILLOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RABBIT; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, FUNGAL; FEMALE; LUNG; LUNG DISEASES, FUNGAL; MICROBIAL SENSITIVITY TESTS; RABBITS; SPECIES SPECIFICITY;

EID: 0042816537     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377210     Document Type: Article

References (59)

1. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992;14 (Suppl i):S43-53.
2. Andriole VT. Infections with Aspergillus species. Clin Infect Dis 1993; 17(Suppl 2):S481-6.
3. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
4. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus study. Medicine (Baltimore) 2000; 79:250-60.
5. Pannuti C, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow transplant: attributable mortality and risk factors. Cancer 1992; 69:2653-62.
6. Iwen PC, Rupp ME, Langnas AN, Reed EC, Hinrichs SH. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin Infect Dis 1998; 26:1092-7.
7. Schett G, Casati B, Willinger B, et al. Endocarditis and aortal embolization caused by Aspergillus terreus in a patient with acute lymphoblastic leukemia in remission: diagnosis by peripheral-blood culture. J Clin Microbiol 1998; 36:3347-51.
8. Koshi G, Cherian KM. Aspergillus terreus, an uncommon fungus causing aortic root abscess and pseudoaneurysm. Indian Heart J 1995; 47:265-7.
9. Tiwari S, Singh SM, Jain S. Chronic bilateral suppurative otitis media caused by Aspergillus terreus. Mycoses 1995; 38:297-300.
10. Neumeister B, Hartmann W, Oethinger M, Heymer B, Marre R. A fatal infection with Alternaria alternata and Aspergillus terreus in a child with agranulocytosis of unknown origin. Mycoses 1994; 37:181-5.
11. Goldberg SL, Geha DJ, Marshall WF, Inwards DJ, Hoagland HC. Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole. Clin Infect Dis 1993; 16:803-5.
12. Tritz DM, Woods GL. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts. Clin Infect Dis 1993; 16:118-22.
13. Nakahara Y, Katoh O, Yamada H, Sumida I, Hanada M. Allergic bronchopulmonary aspergillosis caused by Aspergillus terreus presenting with lobar collapse. Intern Med 1992; 31:140-2.
14. Kalina PH, Campbell JR. Aspergillus terreus endophthalmitis in a patient with chronic lymphocytic leukemia. Arch Ophthalmol 1991; 109:102-3.
15. Russack V. Aspergillus terreus myocarditis: report of a case and review of the literature. Am J Cardiovasc Pathol 1990; 3:275-9.
16. Kimura M, Udagawa S, Shoji, A, et al. Pulmonary aspergillosis due to Aspergillus terreus combined with staphylococcal pneumonia and hepatic candidiasis. Mycopathologia 1990; 111:47-53.
17. Bhatnagar NK, Dhasmana JP, Russell GA, Jordan SC. Aspergillus ball thrombus occluding a homograft conduit. Eur J Cardiothorac Surg 1989; 3:270-2.
18. Moore CK, Hellreich MA, Coblentz CL, Roggli VL. Aspergillus terreus as a cause of invasive pulmonary aspergillosis. Chest 1988; 94:889-91.
19. Chang SW, King TE. Aspergillus terreus causing invasive pulmonary aspergillosis with air crescent sign. J Natl Med Assoc 1986; 78:248-53.
20. Tracy SL, McGinnis MR, Peacock JE Jr, Cohen MS, Walker DH. Disseminated infection by Aspergillus terreus. Am J Clin Pathol 1983; 80:728-33.
21. Laham MN, Carpenter JL. Aspergillus terreus, a pathogen capable of causing infective endocarditis, pulmonary mycetoma, and allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1982; 125:769-72.
22. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A. Wayne, PA: NCCLS, 2001.
23. Levitz SM, Diamond RD. A rapid colorimetric assay of fungal viability with tetrazolium salt MTT. J Infect Dis 1985; 152:938-45.
24. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by neutrophils to Aspergillus fumigatus hyphae by granulocyte colony stimulating factor and interferon-gamma. Infect Immun 1993; 61:1185-93.
25. Ghannoum MA, Swairjo I, Soll DR. Variation in lipid and sterol contents in Candida albicans white and opaque phenotypes. J Med Vet Mycol 1990; 28:103-15.
26. Vandenheuvel FA, Court AS. Reference high-efficiency nonpolar packed columns for the gas-liquid chromatography of nanogram amounts of steroids. I. Retention time data. J Chromatogr 1968; 38:439-59.
27. Vandenheuvel FA, Court AS. Reference high-efficiency nonpolar packed columns for the gas-liquid chromatography of nanogram amounts of steroids. II. Identification of steroids. J Chromatogr 1969; 39:1-16.
28. Roilides E, Sein T, Holmes A, et al. Effects of macrophage colony stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Infect Dis 1995; 172:1028-34.
29. Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press, 1996.
30. Walsh TJ, Bacher J, Pizzo PA. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits. Lab Anim Sci 1988; 38:467-71.
31. Sutton DA, Fothergill AW, Rinaldi MG. Guide to clinically significant fungi. Baltimore: Williams & Wilkins, 1998:46-69.
32. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar lavage D-mannitol and galactomannan as markers of infection. J Infect Dis 1994; 169:356-68.
33. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and plasma pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45:857-69.
34. Walsh TJ, McEntee C, Dixon DM. Tissue homogenization for quantitative cultures of Candida albicans using sterile reinforced polyethylene bags. J Clin Microbiol 1987; 25:931-2.
35. Stynen D, Sarfati J, Goris A, et al. Rat monoclonal antibodies against Aspergillus galactomannan. Infect Immun 1992; 60:2237-45.
36. Walsh TJ, Garrett K, Feuerstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography: a novel non-invasive method for measuring responses of organism-mediated tissue injury. Antimicrob Agents Chemother 1995; 39:1065-9.
37. Flynn PM, Williams BG, Hetherington SV, Williams BF, Giannini MA, Pearson TA. Aspergillus terreus during hospital renovation. Infect Control Hosp Epidemiol 1993; 14:363-5.
38. Lass-Florl C, Rath P, Niederwieser D, et al. Aspergillus terreus infections in haematological malignancies: molecular epidemiology suggests association with in-hospital plants. J Hosp Infect 2000; 46:31-5.
39. Anaissie EJ, Stratton SL, Summerbell RC, et al. Pathogenic Aspergillus species recovered from a hospital water system: a three-year prospective study. Clin Infect Dis 2002; 34:780-9.
40. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000; 31:188-9.
41. Latge J. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12:310-50.
42. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a routine model of disseminated aspergillosis. J Med Microbiol 2000; 49:601-6.
43. Lass-Florl C, Kofler G, Kropshofer G, et al. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42:497-502.
44. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30:696-709.
45. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803.
46. Walsh TJ, Groll AH. Non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Invest Drugs 2001; 2:1366-7.
47. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954-8.
48. Espinel-Ingroff A, Bartlett M, Bowden R, et al. A multicenter evaluation of the standardization of antifungal susceptibility testing for filamentous fungi. J Clin Microbiol 1997; 35:139-43.
49. Walsh TJ, Peter J, McGough DA, Fothergill AW, Rinaldi MG, Pizzo PA. Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii. Antimicrob Agents Chemother 1995; 39:1361-4.
50. Walsh TJ, Melcher G, Rinaldi M, et al. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B. J Clin Microbiol 1990; 28:1616-22.
51. Walsh TJ, Lee JW, Melcher GP, et al. Experimental disseminated trichosporonosis in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic infection. J Infect Dis 1992; 166:121-33.
52. Anaissie EJ, Hachem R, Legrand C, Legenne P, Nelson P, Bodey GP. Lack of activity of amphotericin B in systemic murine fusarial infection. J Infect Dis 1992; 165:1155-7.
53. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999-1008.
54. Karyotakis NC, Anaissie EJ, Hachem R, Dignani MC, Samonis G. Comparison of the efficacy of polyenes and triazole against hematogenous Candida krusei infection in neutropenic mice. J Infect Dis 1993; 168:1311-3.
55. Sutton DA, Sanche SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37:2343-5.
56. Odds FC, Van Gerven F, Espinel-Ingroff A, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal outcomes in animal infection models. Antimicrob Agents Chemother 1998; 42:282-8.
57. Klich, MA, Pitt JI. A laboratory guide to common Aspergillus species and their teleomorphs. North Ryde, New South Wales, Australia: Commonwealth Scientific and Industrial Research Organization, 1988.
58. Seligsohn R, Rippon JW, Lerner SA. Aspergillus terreus osteomyelitis. Arch Intern Med 1977; 137:918-20.
59. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol 1998; 109:45-54.